GuoLine Advisory’s Regeneron Pharmaceuticals REGN Stock Holding History

GuoLine Advisory’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$42M	Hold	67,300	–	–	3.91%	8
2026 Q1	$52M	Hold	67,300	–	–	5.44%	5
2025 Q4	$51.9M	Hold	67,300	–	–	4.78%	5
2025 Q3	$37.8M	Hold	67,300	–	–	3.77%	10
2025 Q2	$35.3M	Buy	67,300 +11,000	+20%	+$6.14M	3.75%	11
2025 Q1	$35.7M	Buy	56,300 +9,940	+21%	+$6.84M	3.78%	12
2024 Q4	$33M	Buy	46,360 +14,300	+45%	+$12M	3.41%	13
2024 Q3	$33.7M	Hold	32,060	–	–	3.43%	16
2024 Q2	$33.7M	Buy	32,060 +6,160	+24%	+$5.97M	3.6%	16
2024 Q1	$24.9M	Buy	+25,900	New	+$24.6M	3.04%	18

Other funds holding REGN

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

MCI

McDonald Capital Investors Orinda, California $1.37B AUM 1.88% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Retirement Systems of Alabama Montgomery, Alabama $33.2B AUM 38.15% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Parnassus Investments San Francisco, California $37.4B AUM 35.42% 1-Year Est. Return

GuoLine Advisory's REGN Position: Q2 2026 in Review

GuoLine Advisory held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 67,300 shares worth $42M. The position accounts for 3.91% of the portfolio, ranked #8.

GuoLine Advisory first reported a position in REGN in Q1 2024 and has held it in 10 quarters since. The position peaked at $52M in Q1 2026. 518 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

GuoLine Advisory held 67,300 shares of Regeneron Pharmaceuticals worth $42M as of Q2 2026.
GuoLine Advisory left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
Regeneron Pharmaceuticals made up 3.91% of GuoLine Advisory's portfolio in Q2 2026, its #8 holding.
GuoLine Advisory first reported a position in Regeneron Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
GuoLine Advisory's Regeneron Pharmaceuticals position peaked at $52M in Q1 2026.
518 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on GuoLine Advisory's 13F filing for Q2 2026, filed 16 Jul 2026.